trolamine salicylate has been researched along with Acquired Form of Epidermolysis Bullosa in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beneduce, C; Bhatnagar, N; Bosques, CJ; Brown, J; Capila, I; Child, M; Choudhury, A; Hains, M; Holte, K; Killough, J; Kurtagic, E; Lansing, JC; Ling, L; Manning, AM; Markowitz, L; Meccariello, R; Nguyen, S; Nimmerjahn, F; Ortiz, DF; Prenovitz, R; Prod'homme, T; Rutitzky, L; Schultes, B; Schwab, I; Simpson, A; Tyler, S; Wang, J; Washburn, N; Zouaoui, R | 1 |
1 other study(ies) available for trolamine salicylate and Acquired Form of Epidermolysis Bullosa
| Article | Year |
|---|---|
Elucidating the interplay between IgG-Fc valency and FcγR activation for the design of immune complex inhibitors.
Topics: Animals; Antibodies, Monoclonal; Antibody-Dependent Cell Cytotoxicity; Antigen-Antibody Complex; Arthritis; Arthritis, Experimental; Autoantibodies; Autoimmune Diseases; Cell Line; Epidermolysis Bullosa Acquisita; Humans; Immune Complex Diseases; Immunoglobulin Fc Fragments; Immunoglobulin G; Male; Mice; Mice, Inbred C57BL; Monocytes; Phagocytes; Platelet Activation; Purpura, Thrombocytopenic, Idiopathic; Receptors, IgG; Signal Transduction | 2016 |